Medicus Pharma submits optimized Phase 2 Teverelix trial protocol to FDA

Medicus Pharma (NASDAQ:MDCX) announced on Monday that it has submitted an optimized Phase 2 clinical study protocol to the US Food and Drug Administration (FDA) for Teverelix, an investigational GnRH antagonist. The study is designed to evaluate the drug's effectiveness in preventing recurrent acute urinary retention (AURr) in men with benign prostatic hyperplasia (BPH) as part of an existing open Investigational New Drug application.